Dongyi· Business · 6 sources · Sep 3, 2026StoryCipla and Qilu ink exclusive deal to sell Keytruda biosimilar in USInvagen Pharmaceuticals has signed an exclusive US licensing deal with Qilu Pharmaceutical to commercialize QL2107, a Keytruda (pembrolizumab) biosimilar, with Qilu handling development, regulatory work, and supply while Cipla USA drives commercialization. The arrangement underscores Cipla’s strategy to expand its oncology-focused biosimilars portfolio and reduce cancer treatment costs for patients, following multiple collaborations with Chinese manufacturers.Business· Sep 3, 2026+3+23ShareDerek Foss·Sep 4, 2026Top commentPatent cliff for Keytruda can't come soon enough. Hope this actually translates to lower prices once it hits the US market, not just corporate profit shifting.00ReplyGenius replyShareWrite a comment…